Silence Therapeutics heads into its August 12 results with the stock in the middle of one of its sharpest rallies in recent memory — and the insider register telling a story that cuts against the bullish momentum.
The clearest tension is between price and insider behaviour. The stock climbed 29% in a single session on August 10 and has now gained 70% over the past month, closing at $15.43. Yet the company's largest shareholder, Richard Griffiths, sold more than 1.5 million shares in late June and early July — collecting roughly $16.4 million in net proceeds — at prices around $10.50 to $10.76. That disposal, representing close to a quarter of the company's float at the time, came well below current levels, making it the defining context for how confident the inside money actually was in the near-term setup.
Options positioning reinforces the bullish tilt rather than hedging it. The put/call ratio is running at a notably low 0.17 — close to a 52-week floor of 0.04, and barely above its 20-day average of 0.16 — a signal that call demand is dominant and investors are leaning heavily toward upside participation. The borrow market offers no friction for that view: availability is generous at roughly 510%, meaning there are more than five shares available to lend for every one already borrowed, and cost to borrow is a low 0.57%. Short interest has also been declining steadily, falling around 24% over the past month to just 1.57 million shares. Whatever bearish pressure once existed in the borrow market has largely cleared.
The analyst community is uniformly bullish by rating, but the targets span a wide range and some are dated. HC Wainwright holds a $75 target reiterated in June, while Chardan carries a $35 target. The mean across the coverage sits near $30 — roughly double the current price — though Morgan Stanley cut its target to $25 from $45 in May 2025, and Goldman Sachs carries a Sell rating with a $3 target, a figure that now looks dramatically stale relative to where the stock trades. Bulls point to validated clinical data on hepcidin engagement and ferritin elevation in iron deficiency, with near-term pipeline milestones as catalysts. Bears flag the company's pre-profitability position — a deeply negative EV/EBITDA, negative earnings yield, and reliance on a pipeline that has yet to generate diversified revenue.
The earnings print will test whether the clinical and business development narrative behind the July-August rally has enough concrete substance — new data, a partnership signal, or upgraded guidance — to justify a price that now sits at twice the level where the company's largest insider was selling just six weeks ago.
See the live data behind this article on ORTEX.
Open SLN on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
